© Copyright Nostre Net
Market Scope
The tenecteplase
drug market Share is expected to reach USD 2,455.4 million by 2030 at 5.10%
CAGR during the forecast period 2022-2030.Tenecteplase drug refers to a
recombinant enzyme that acts as a blood thinning agent. Also known as a clot
buster, tenecteplase drug helps dissolve blood clots or clumps, allowing the
blood to flow normally. These drugs are generally used for treating patients
facing heart-related issues.
Some of the leading factors influencing the market growth
include the increasing number of hypertension patients, rising number of deep
vein thrombosis cases, early aging, and sedentary lifestyles that lead to blood
clotting. The American Heart Association reported in 2017 that every 40
seconds, an individual in the United States (U.S) gets a heart attack.
Additionally, the report states that coronary heart disease
(CHD), which accounts for 43.8% is the main cause of deaths due to
cardiovascular disease (CVD) in the United States (US). Whereas, heart failure
(HF) (9.0%), high BP (9.4%), stroke (16.8%), and other CVDs (17.9%) are other
causes for deaths in the country. Furthermore, the report expects that by 2035,
over 130 million adults in the US, around 45.1%, will suffer from some form of
CVD. As a result, the overall costs of CVD are estimated to touch the valuation
of USD 1.1 trillion by 2035. Therefore, the hike in the rate of cardiovascular
diseases is projected to stimulate the tenecteplase drug market growth in the
years ahead.
Market Segmentation
The worldwide tenecteplase
drug market outlook has been segmented on the basis of application, dosage,
and end users.
The tenecteplase drug market, with respect to application,
is considered for myocardial infarction, stroke, DVT.
As per dosage, tenecteplase drug market can be broken down
into intravenous dosage and intracatheter instillation dosage.
The end-users in the market are hospitals and clinics,
surgical centers, research centers.
Regional Insight
The key markets for tenecteplase drug include Europe, Asia
Pacific, the Middle East, and Africa and North America.
North America has been estimated as the biggest market for
tenecteplase drug, on account of the rising innovations in clinical practice
and surge in myocardial infection. The region also benefits from increasing
access to stroke treatment, supported by the sophistication of healthcare
infrastructure in the region. An article by CDC in 2015 suggested that in the
United States (U.S.), close to 350,000 to 900,000 cases of Venous
thromboembolism (VTE) are estimated annually. These statistics point towards
the high potential of the tenecteplase drug market in North America.
Europe is the second most profitable market for tenecteplase
drug, with the chief reason being the increase in incidents of stroke. The
United Kingdom (UK) Organization has identified stroke as the 10th primary
cause of death globally, with 34,883 mortality cases found in the UK alone in
the year 2015. As a result of a surge in hypertension as well as high blood
pressure, the stroke cases are on the rise in the region, elevating the market
position of tenecteplase drug.
Key Companies
The key companies present in the worldwide tenecteplase drug
market include Genentec Inc., Gennova pharmaceutical, Merck Ltd., Hisun USA,
Boehringer Ingelheim International GmbH, Crunchbase Inc., Rewine
pharmaceuticals, Emcure Pharmaceutical, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
The Wall